In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide

• Published in: Vaccine 2009-10, Vol.27 (44), p.6107-6109
• Main Authors: Balasse, Emilie, Gatouillat, Gregory, Patigny, Dominique, Andry, Marie Christine, Madoulet, Claudie
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Antigens, Neoplasm - immunology; Cancer Vaccines - immunology; Cancer Vaccines - therapeutic use; CD4-Positive T-Lymphocytes - immunology; Cell Line, Tumor; Female; Immunotherapy; MART-1 Antigen; Melanoma - immunology; Melanoma - therapy; Mice; Molecular Sequence Data; Neoplasm Proteins - immunology; Peptides - immunology
• ISSN: 1873-2518
• DOI: 10.1016/j.vaccine.2009.07.109

Malignant melanoma causes significant health problems. The identification of tumour-associated antigens has led to novel approaches to increase T cell mediated anti-tumour immune response. Melan-A/MART-1 has been use as target antigen for several T cell based immunotherapeutic treatments. More recently, the critical role of CD4+ T cells in inducing and maintaining anti-tumour immunity has been increasingly recognized. In order to optimize tumour immunotherapy, greater efforts have been concentrated on the identification of tumour antigens presented by MHC class II molecules to CD4+ T cells. In a publication, Tiwari et al. (2004) [1] have identified by a computational approach the 15-mer amino-acid sequence 101-115 (PPAYEKLSAEQSPPP) of the Melan-A/MART-1 as a good target for a vigorous and safe immunotherapy. Therefore, we have investigated the in vivo anti-tumour activity of this peptide in a murine melanoma model. For the prophylactic treatment, 20microg or 50microg peptide was subcutaneously injected in mice once a week during 3 weeks before tumour induction. Treatment with 50microg peptide significantly affected tumour development. Thus, our preliminary data demonstrate potential in vivo prophylactic activity of the 101-115 peptide-based vaccine to control melanoma growth.